Furthermore, SGLT2 is functionally expressed in various cancers including pancreatic, prostate [13], liver [14], and colon cancers [15], and SGLT2 inhibitors (SGLT2-Is) exhibit antitumor effects on these cancers [16]. This evidence concerns the gene SLC5A2 and malignant colon neoplasm.